Video
Dr. William Huang on UGN-102 in non–muscle-invasive bladder cancer
Author(s):
“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.
In this interview, recorded at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana, William C. Huang, MD, discusses the OPTIMA II and ENIVISION trials evaluating UGN-102 in non–muscle-invasive bladder cancer. Huang is professor and vice chair for clinical affairs in the Department of Urology at NYU Grossman School of Medicine in New York, New York.
Related Videos
Related Content
